首页> 外文期刊>Bioorganic and medicinal chemistry >Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines
【24h】

Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines

机译:用碳酸酐酶I,II和IX抑制活性的4-(噻唑-2-基氨基氨基) - 苯磺酰胺抑制活性和对乳腺癌细胞系的细胞毒性作用

获取原文
获取原文并翻译 | 示例
           

摘要

A series of 4-(thiazol-2-ylamino)-benzenesulfonamides was synthesized and screened for their carbonic anhydrase (CA, EC 4.2.1.1) inhibitory and cytotoxic activity on human breast cancer cell line MCF-7. Human (h) CA isoforms I, II and IX were included in the study. The new sulfonamides showed excellent inhibition of all three isoforms, with K(I)s in the range of 0.84-702 nM against hCA I, of 0.41-288 nM against hCA II and of 5.6-29.2 against the tumor-associated hCA IX, a validated anti-tumor target, with a sulfonamide (SLC-0111) in Phase I clinical trials for the treatment of hypoxic, metastatic solid tumors overexpressing CA IX. The new compounds showed micromolar inhibition of growth efficacy against breast cancer MCF-7 cell lines. (C) 2016 Elsevier Ltd. All rights reserved.
机译:合成了一系列4-(噻唑-2-基氨基) - 苯磺酰胺,并筛选它们的碳酸酐酶(CA,EC 4.2.1.1)对人乳腺癌细胞系MCF-7上的抑制性和细胞毒性活性。 人体(H)CA同种型I,II和IX被包括在研究中。 新的磺胺酰胺显示出对所有三种同种型的优异抑制,k(i)均在0.84-702nm的范围内,抗HC球I的0.41-288nm,以及5.6-29.2针对肿瘤相关的HCA IX, 验证的抗肿瘤靶标,含有磺酰胺(SLC-0111)的I型临床试验,用于治疗缺氧,转移性固体肿瘤过度表达CA10X。 新化合物显示微摩尔对乳腺癌MCF-7细胞生长效果的抑制。 (c)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号